Current and emerging pharmacological therapy for non-alcoholic fatty liver disease - Hallo friendsTHE LEK NEWS, In the article you read this time with the title Current and emerging pharmacological therapy for non-alcoholic fatty liver disease, We have prepared this article for you to read and retrieve information therein. Hopefully the contents of postings Article culture, Article economy, Article health, Article healthy tips, Article news, Article politics, Article sports, We write this you can understand. Alright, good read.

Title : Current and emerging pharmacological therapy for non-alcoholic fatty liver disease
link : Current and emerging pharmacological therapy for non-alcoholic fatty liver disease

Current and emerging pharmacological therapy for non-alcoholic fatty liver disease

Editorial
World J Gastroenterol. Nov 14, 2017; 23(42): 7495-7504
Published online Nov 14, 2017. doi: 10.3748/wjg.v23.i42.7495

Full Text Article Available Online
http://ift.tt/2zEQlIK

Current and emerging pharmacological therapy for non-alcoholic fatty liver disease
The main treatment of patients with non-alcoholic fatty liver disease (NAFLD) is life style modification including weight reduction and dietary regimen. Majority of patients are safely treated with this management and pharmacologic interventions are not recommended. However, a subgroup of NAFLD patients with non-alcoholic steatohepatitis (NASH) who cannot achieve goals of life style modification may need pharmacological therapy. One major obstacle is measurement of histological outcome by liver biopsy which is an invasive method and is not recommended routinely in these patients. Several medications, mainly targeting baseline mechanism of NAFLD, have been investigated in clinical trials for treatment of NASH with promising results. At present, only pioglitazone acting as insulin sensitizing agent and vitamin E as an anti-oxidant have been recommended for treatment of NASH by international guidelines. Lipid lowering agents including statins and fibrates, pentoxifylline, angiotensin receptor blockers, ursodeoxycholic acid, probiotics and synbiotics are current agents with beneficial effects for treatment of NASH but have not been approved yet. Several emerging medications are in development for treatment of NASH. Obeticholic acid, liraglutide, elafibranor, cenicriviroc and aramchol have been tested in clinical trials or are completing trials. Here in, current and upcoming medications with promising results in clinical trial for treatment of NAFLD were reviewed.

Core tip: Non-alcoholic fatty liver disease (NAFLD) is an increasing liver disease worldwide. However, most of patients are treated with life style modification including weight loss and dietary regimen. Pharmacologic therapy may be indicated in a group of patients with non-alcoholic steatohepatitis. Here in, the current and emerging medications for treatment of NAFLD was reviewed briefly with regard of their beneficial effects on histological outcomes.

Full Text: http://ift.tt/2zEQlIK

Thus Article Current and emerging pharmacological therapy for non-alcoholic fatty liver disease

That's an article Current and emerging pharmacological therapy for non-alcoholic fatty liver disease This time, hopefully can give benefits to all of you. well, see you in posting other articles.

You are now reading the article Current and emerging pharmacological therapy for non-alcoholic fatty liver disease with the link address https://theleknews.blogspot.com/2017/11/current-and-emerging-pharmacological.html

Tweet

Subscribe to receive free email updates: